Changes and clinical impact of HER3 and <i>ERBB3</i> expression in primary and recurrent ovarian cancer.
- DOI
- 10.3802/jgo.2027.38.e30
- Published
- 2026-09-11
- Container
- J Gynecol Oncol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3802/jgo.2027.38.e30,
title = {Changes and clinical impact of HER3 and \<i\>ERBB3\</i\> expression in primary and recurrent ovarian cancer.},
author = {Yokosu K and Yamashita R and Fujii S and Tanabe H and Mukohara T and Sato S and Kobayashi M and Oshima K and Kimura H and Takahashi H and Saito M and Yamada K and Takano H and Okamoto A and Harano K.},
year = {2026},
journal = {J Gynecol Oncol},
doi = {10.3802/jgo.2027.38.e30},
url = {https://doi.org/10.3802/jgo.2027.38.e30}
}RIS
TY - JOUR TI - Changes and clinical impact of HER3 and <i>ERBB3</i> expression in primary and recurrent ovarian cancer. AU - Yokosu K AU - Yamashita R AU - Fujii S AU - Tanabe H AU - Mukohara T AU - Sato S AU - Kobayashi M AU - Oshima K AU - Kimura H AU - Takahashi H AU - Saito M AU - Yamada K AU - Takano H AU - Okamoto A AU - Harano K. PY - 2026 JO - J Gynecol Oncol DO - 10.3802/jgo.2027.38.e30 UR - https://doi.org/10.3802/jgo.2027.38.e30 ER -
APA
K, Y., R, Y., S, F., H, T., T, M., S, S., M, K., K, O., H, K., H, T., M, S., K, Y., H, T., A, O., & K., H. (2026). Changes and clinical impact of HER3 and <i>ERBB3</i> expression in primary and recurrent ovarian cancer.. J Gynecol Oncol. https://doi.org/10.3802/jgo.2027.38.e30
Source records
- europe-pmc · retrieved 2026-09-26T06:00:31.020Z